According to a new market research study titled ‘NGS-Based RNA-Seq Market to 2027 – Global Analysis and Forecasts by Product & Services, Technology, Application and End User, the global NGS-based RNA-seq market is expected to reach US$ 7,984.90 Mn in 2027 from US$ 1,240.87 Mn in 2017. The market is estimated to grow with a CAGR of 19.3% from 2018-2027. The report highlights the trends prevalent in the global NGS-based RNA-seq market and the factors driving the market along with those that act as deterrents to its growth.
Get Sample PDF of this Report @ https://www.theinsightpartners.com/sample/TIPBT00002556/
The major players operating in the market of NGS-based RNA-seq include Illumina, Inc., Thermo Fisher Scientific Inc., Pacific Biosciences of California, Inc., Qaigen, F. Hoffmann-La Roche AG, Agilent Technologies, Inc., BGI, Oxford Nanopore Technologies, Perkinelmer, Inc. and Eurofins Scientific among others. The global NGS-based RNA-seq market is highly competitive and driven by advanced products launch and approvals. For instance, in April 2018, BGI launched NGS-based HPV genotyping product, Sentis-HPVseq, to the global market that provides detection of both high-risk and low-risk HPV types, which is recognized as an effective method for primary cervical cancer screening.
The market is expected to grow due to the reduced cost of genome sequencing, advancements in sequencing technology and next generation sequencing for cancer, are the major factors that anticipated to propel the growth for the NGS-based RNA-seq market in the forecast period. However, the risks related to genetic data and high cost of NGS instruments is expected to act as a major challenges hindering the market growth in the forecast period.
Ask For Discount @ https://www.theinsightpartners.com/discount/TIPBT00002556/
The recent development in technologies has enabled companies to produce sequencing in a single day at the cost of about $15 per sample. Genome library automation includes the incorporation of LIMS that is used to provide tracking mechanisms during the sample preparation and incorporation of barcodes to the micro RNA libraries at the PCR step. It results in effective delivery of target and whole genome data for thousands of samples at a reasonable cost. For instance, Illumina’s Multiples Sequencing permits large numbers of libraries to be assembled and sequenced concurrently during a single run on a high-throughput instrument. The barcodes are added to the fragments at the time of next generation sequencing library preparation. The barcode attached with the DNA fragments assists in the identification and sorting the final data for analysis. This is a cost effective treatment and provides high-quality data by maintaining the read lengths of the unknown sequences. Therefore, the NGS-based RNA-seq market is anticipated to grow due to using barcode scanning for long reads sequences, in the forecast period.
The NGS-based RNA sequencing market by product & services is segmented into sequencing platforms and consumables, sample preparation, sequencing services and data analysis, storage and management. In 2018, the sequencing platform & consumables segment held a largest market share of 38.3% of the NGS based RNA sequencing market, by product & services. This segment is also expected to dominate the market in 2027 owing to advantage which include quality of the sequence data, robustness and low noise while performing the sequence and others. Furthermore, the sample preparation segment is anticipated to witness the fastest growth rate during the forecast period, 2018 to 2027.
Purchase this Report @ https://www.theinsightpartners.com/buy/TIPBT00002556/
On the basis of end user, the NGS-based RNA sequencing market is segmented into research centers and academic & government institutes, hospitals & clinics, pharmaceutical & biotechnology companies, and others. In 2018, the research centers segment held a largest market share of 45.0% of the genomics market, by end user. This segment is also expected to dominate the market in 2027. However, the hospitals & clinics segment is anticipated to witness the fastest growth rate of 23.2% during the forecast period, 2018 to 2027. This higher growth rate of the segment owing to the providing the references for further researches are likely to propel the growth of the research centers and academic & government institutes segment in the coming future.
Global NGS-based RNA-seq market, based on the application was segmented into diagnostics, drug discovery, precision medicine and others. In 2017, the diagnostics segment held the largest and fastest growing segment of the market.
Strategic Insights
Product & service launch/update and partnerships, agreements & collaborations were observed as the most adopted strategy in global NGS-based RNA sequencing industry. Few of the strategic developments made by the players in the market are listed below;
2018: In January, Illumina, Inc. launched iSeq 100 Sequencing System that delivers exceptional data accuracy, at a low capital cost, making Illumina technology available to virtually any lab.
2018: In September, QIAGEN N.V. and NeuMoDx Molecular, Inc. entered into a partnership to commercialize two new fully integrated systems for automation of PCR (polymerase chain reaction) testing.
2017: In May, QIAGEN N.V. and Maccura Biotechnology Co., Ltd. entered into a partnership to accelerate local adaptations, development and commercialization of the GeneReader NGS System in the rapidly growing clinical and clinical research markets in China.
Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com